Navigation Links
Stallergenes : 3rd Quarter Sales Up 17%: 9- Month Cumulative Sales Up 17%
Date:10/11/2007

PARIS, October 11 /PRNewswire-FirstCall/ --

(EUR millions) 2007 2006 07/06

%Sales %Sales %

change

Southern Europe (1) 20.63 70.6 17.61 70.7 17

Other EU countries (2) 7.07 24.2 6.06 24.4 17

Other markets 1.51 5.2 1.22 4.9 24

SLIT 22.13 75.8 18.14 72.9 22

SCIT 5.96 20.4 5.60 22.5 6

Other products 1.12 3.8 1.15 4.6 (3)

Total Q3 sales 29.21 100.0 24.89 100.0 17

Southern Europe (1) 77.16 74.2 65.71 73.8 17

Other EU countries (2) 22.83 21.9 19.78 22.2 15

Other markets 4.02 3.9 3.60 4.0 12

SLIT 81.88 78.7 67.55 75.8 21

SCIT 17.78 17.1 17.23 19.3 3

Other products 4.35 4.2 4.31 4.8 1

9-month cumulated sales 104.01 100.0 89.09 100.0 17

(1) Portugal, Spain, France, Italy, Greece;

(2) Switzerland included

Sales growth and financial position

2007 3rd quarter sales registered further significant growth in all markets (+17%, vs +9% in 2006). The most vigorous market segment remained sublingual route desensitization (SLIT, +22%). Subcutaneous route sales (SCIT) increased by 6%. Cumulative sales for the first nine months of the year increased by 17% (vs +13% in 2006).

The financial position improved. Net debt declined 40% from net debt at 30 September 2006.

Significant 3rd quarter transactions and events

The new allergen production facility has been completed. Collection and validation operations are being implemented within the planned timeframe.

The market authorisation procedure for the ORALAIR(R) Grasses allergen tablet by the P.E.I. German agency is still ongoing. Management is confident the procedure will soon be completed.

Outlook for the current year

The Group now provides guidance of 12% to 14% full-year sales growth and profitability close to that of 2006 in absolute value.

About Stallergenes

Stallergenes is a European biopharmaceutical company dedicated to desensitization treatments for the prevention and cure of allergy-related respiratory diseases, e.g. rhino-conjunctivitis and allergic asthma.

A pioneer and leader in sublingual desensitization treatments, Stallergenes devotes more than 15% of its sales to Research and Development and is today fully involved in the development of a new therapeutic family, the sublingual desensitization tablets.

With a registered office in France, Stallergenes markets its products in approximately 40 countries. Stallergenes realised 2006 sales of EUR 126.5 million, of which half outside France.

Stallergenes' shares are listed on Eurolist Compartment B of the Euronext Paris Stock Exchange.

ISIN code: FR0000065674, Reuters code: GEN.PA, Bloomberg code: GEN.FP

For additional information on Stallergenes, please visit our website: http://finance.stallergenes.com


'/>"/>
SOURCE Stallergenes
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Midwest life science stocks sizzle in a tepid first quarter
2. CIOs looking to hire more IT workers in second quarter
3. Fiserv posts 30 percent quarterly loss
4. Sonic Foundry reports first cash-positive quarter
5. Venture capital above $6B for third straight quarter
6. Third Wave reports $5.2M third quarter loss
7. Inventions could fall prey to Monday morning quarterbacking
8. Merge fails to file quarterly financial report
9. Rexnord to slash debt after quarterly loss
10. Johnson Controls reports record quarterly sales
11. Sonic Foundry reports quarterly loss, higher Mediasite sales
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... At its ... announced Dr. Suneel I. Sheikh, the co-founder, CEO and chief research scientist of ... been selected for membership in ARCS Alumni Hall of Fame . ASTER ...
(Date:10/11/2017)... , Oct. 11, 2017  VMS BioMarketing, a leading ... a nationwide oncology Clinical Nurse Educator (CNE) network, which will ... need for communication among health care professionals to enhance the ... nurses, office staff, and other health care professionals to help ... breast cancer. ...
(Date:10/10/2017)... ... October 10, 2017 , ... San Diego-based team building and cooking ... initiative announced today. The bold new look is part of a transformation to ... into a significant growth period. , It will also expand its service offering from ...
(Date:10/10/2017)... Oct. 10, 2017 SomaGenics announced the receipt ... to develop RealSeq®-SC (Single Cell), expected to be the ... RNAs (including microRNAs) from single cells using NGS methods. ... need to accelerate development of approaches to analyze the ... "New techniques for measuring levels of mRNAs in ...
Breaking Biology Technology:
(Date:6/14/2017)... 15, 2017  IBM (NYSE: IBM ) is introducing several ... dedicated to developing collaboration between startups and global businesses, taking ... During the event, nine startups will showcase the solutions they ... industries. France is ... with a 30 percent increase in the number of startups ...
(Date:5/16/2017)... , May 16, 2017   Bridge ... health organizations, and MD EMR Systems , ... development partner for GE, have established a partnership ... Portal product and the GE Centricity™ products, including ... EMR. These new integrations will ...
(Date:4/19/2017)... April 19, 2017 The global ... landscape is marked by the presence of several large ... held by five major players - 3M Cogent, NEC ... accounted for nearly 61% of the global military biometric ... in the global military biometrics market boast global presence, ...
Breaking Biology News(10 mins):